Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
This study has been completed.
Study NCT00000973 Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999 Last Updated: July 31, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Toxoplasmosis, Cerebral
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Communicable Diseases
Infection
Toxoplasmosis
More general conditions related to this trial
Abscess
Brain Abscess
Brain Diseases
Central Nervous System Diseases
Central Nervous System Infections
Central Nervous System Parasitic Infections
Central Nervous System Protozoal Infections
Coccidiosis
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Nervous System Diseases
Parasitic Diseases
Protozoan Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Suppuration
Virus Diseases
Interventions listed in this trial
Pyrimethamine
Leucovorin calcium
Zidovudine
Additional drug interventions recognized in this trial
Leucovorin
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antimalarials
Antimetabolites
Antiparasitic Agents
Antiprotozoal Agents
Antiviral Agents
Enzyme Inhibitors
Folic Acid Antagonists
Growth Substances
Micronutrients
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Reverse Transcriptase Inhibitors
Therapeutic Uses
Vitamin B Complex
Vitamins
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)
Glaxo Wellcome
Back to top of Main Content